Abstract:Duchenne muscular dystrophy (DMD) is a fatal X-linked recessive disease due to loss-of-function mutations in the gene. DMD-related skeletal muscle wasting is typified by an aberrant immune response involving upregulation of TGFβ family of cytokines. We previously demonstrated that bone morphogenetic protein 4 (BMP4) is increased in DMD and BMP4 stimulation induces a 20-fold upregulation of transcription. However, the role of BMP4 in severely affected DMD skeletal muscle is unknown. We hypothesized that transcriptomic signatures in severely affected human DMD skeletal muscle are driven by BMP4 signaling. Transcriptomes from skeletal muscle biopsies of late-stage DMD vs. non-DMD controls and C2C12 muscle cells with or without BMP4 stimulation were generated by RNA-Seq and analyzed for single transcript differential expression as well as by Ingenuity Pathway Analysis and weighted gene co-expression network analyses. A total of 2,328 and 5,291 transcripts in the human muscle and C2C12 muscle cells, respectively, were differentially expressed. We identified an overlapping molecular signature of 1,027 genes dysregulated in DMD muscle that were induced in BMP4-stimulated C2C12 muscle cells. Highly upregulated DMD transcripts that overlapped with BMP4-stimulated C2C12 muscle cells included , and The DMD transcriptome was characterized by dysregulation of pathways involving immune function, extracellular matrix remodeling, and metabolic/mitochondrial function. In summary, we define a late-stage DMD skeletal muscle transcriptome that substantially overlaps with the BMP4-induced molecular signature in C2C12 muscle cells. This supports BMP4 as a disease-driving regulator of transcriptomic changes in late-stage DMD skeletal muscle and expands our understanding of the evolution of dystrophic signaling pathways and their associated gene networks that could be explored for therapeutic development.

BMP Antagonists Enhance Myogenic Differentiation and Ameliorate the Dystrophic Phenotype in a DMD Mouse Model

Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor.

Targeting TGF-|[beta]| Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-|[beta]| Type I Receptor

O.13 Interference of Myostatin and TGF-beta Signaling by Antisense-Mediated Exon Skipping in ALK4/5 Receptors

PTEN Inhibition Ameliorates Muscle Degeneration and Improves Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy

Late-Stage Skeletal Muscle Transcriptome in Duchenne muscular dystrophy shows a BMP4-Induced Molecular Signature

PTPN1/2 inhibition promotes muscle stem cell differentiation in Duchenne muscular dystrophy

Angiotensin II Type 1 Receptor Antagonists Alleviate Muscle Pathology in the Mouse Model for Laminin-Α2-deficient Congenital Muscular Dystrophy (MDC1A)

Overactive Bone Morphogenetic Protein Signaling in Heterotopic Ossification and Duchenne Muscular Dystrophy

Tetramethylpyrazine Nitrone Improved Motor Deficits and Alleviated Dystrophic Muscle Pathology in the Mdx Mouse Model of Duchenne Muscular Dystrophy

New Function of the Myostatin/activin Type I Receptor (ALK4) As a Mediator of Muscle Atrophy and Muscle Regeneration

Systemic inhibition of bone morphogenetic protein 1.3 as a possible treatment for laminin-related congenital muscular dystrophy

Next-Generation SINE Compound KPT−8602 Ameliorates Dystrophic Pathology in Zebrafish and Mouse Models of DMD

Inhibition of sphingolipid de novo synthesis counteracts muscular dystrophy

Behavioral, Biochemical and Pathological Characterization of a New MDX Mouse Model of Duchenne Muscular Dystrophy

Adiponectin-receptor agonism prevents right ventricular tissue pathology in a mouse model of Duchenne muscular dystrophy

An anti-ADAMTS1 treatment relieved muscle dysfunction and fibrosis in dystrophic mice

Mineralocorticoid Receptor Antagonists in Muscular Dystrophy Mice During Aging and Exercise

Apelin stimulation of the vascular skeletal muscle stem cell niche enhances endogenous repair in dystrophic mice

Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy

Muscle-specific microRNA-206 targets multiple components in dystrophic skeletal muscle representing beneficial adaptations